Q-omics provides the consensus-scored PRSS21 profile across patient tissues and cancer cell-line models. PRSS21 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in THYM. Among the 18 cancer types available for tumor–normal comparison, PRSS21 is differentially expressed in 9, with the highest sampling consensus in STAD. Additionally, PRSS21 RNA expression shows 8,809 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight THYM, STAD, and HNSC as cancer lineages where PRSS21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRSS21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRSS21 survival associations across molecular data types. PRSS21 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRSS21 RNA expression–survival associations across cancer types. High PRSS21 expression shows unfavorable associations in LGG and GBM, but favorable associations in THYM, OV, LUAD and READ. The THYM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify THYM as the clearest survival context for PRSS21 RNA expression.
This table summarizes PRSS21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 1. The strongest signals are observed in STAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PRSS21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRSS21 shows lower tumor expression in PRAD and higher tumor expression in STAD, KIRC, ESCA, CHOL and KIRP. The STAD box plot shows higher PRSS21 RNA expression in tumor versus normal tissue (log2 FC = +2.514, t-test p < 0.001).
This table shows molecular features associated with PRSS21 in patient tissues and cancer cell lines. In patient samples, PRSS21 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, PRSS21 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
